Gastroenterology and Hepatology

17-32 of 58

Advances in Colorectal Cancer Detection: Exploring the Role of Blood-Based Tests
Advances in Colorectal Cancer Detection: Exploring the Role of Blood-Based Tests
GI Insights
Advances in Colorectal Cancer Detection: Exploring the Role of Blood-Based Tests
- Peter Buch, MD, FACG, AGAF, FACP
- Aasma Shaukat, MD, MPH
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Project Oncology®
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
- Jennifer Caudle, DO, FACOFP
- Samuel Klempner, MD
- Nataliya Uboha, MD, PhD
MinuteCE®
Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making  
0.50 credits 4 episodes
- James M. Cleary, MD, PhD
0.50 credits 4 episodes
Postcolonoscopy Colorectal Cancer: Optimizing Quality to Reduce Risk
Postcolonoscopy Colorectal Cancer: Optimizing Quality to Reduce Risk
Clinician's Roundtable
Postcolonoscopy Colorectal Cancer: Optimizing Quality to Reduce Risk
- Aasma Shaukat, MD, MPH
Blood-Based Screening for Colorectal Cancer: Benefits and Limitations
Blood-Based Screening for Colorectal Cancer: Benefits and Limitations
Clinician's Roundtable
Blood-Based Screening for Colorectal Cancer: Benefits and Limitations
- Aasma Shaukat, MD, MPH
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
Project Oncology®
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
- Ryan Quigley
- Hallie Blevins, PhD
- Marlene Mimi Maeusli, PhD.
Using FTIR to Support Accurate Tissue Assessment in Colorectal Surgery
Using FTIR to Support Accurate Tissue Assessment in Colorectal Surgery
Clinician's Roundtable
Using FTIR to Support Accurate Tissue Assessment in Colorectal Surgery
- Ashley Baker, MSN, PMHNP
- Heather Allen, PhD
- Ran Li, PhD
Initiating Colorectal Cancer Screening Earlier: A Look at the Evidence
Initiating Colorectal Cancer Screening Earlier: A Look at the Evidence
Clinician's Roundtable
Initiating Colorectal Cancer Screening Earlier: A Look at the Evidence
- Theodore Levin, MD
Improving Colorectal Cancer Screening Adherence: Advantages of FIT
Improving Colorectal Cancer Screening Adherence: Advantages of FIT
Clinician's Roundtable
Improving Colorectal Cancer Screening Adherence: Advantages of FIT
- Theodore Levin, MD
Boosting Colorectal Cancer Re-Screening: The Role of Spanish Language Navigation
Boosting Colorectal Cancer Re-Screening: The Role of Spanish Language Navigation
Clinician's Roundtable
Boosting Colorectal Cancer Re-Screening: The Role of Spanish Language Navigation
- Ryan Quigley
- Mallik Greene, PhD
Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
Clinician's Roundtable
Optimizing Colorectal Cancer Screening: A Stress Test of Current Guidelines
- Pedro Nascimento de Lima, PhD
Supplement Use for Colorectal Cancer Prevention: Insights from NCCN Guidelines
Supplement Use for Colorectal Cancer Prevention: Insights from NCCN Guidelines
Clinician's Roundtable
Supplement Use for Colorectal Cancer Prevention: Insights from NCCN Guidelines
- Reid Ness, MD
Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19
Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19
Clinician's Roundtable
Disaster-Proofing Colorectal Cancer Screening: What We Learned from COVID-19
- Charles Turck, PharmD, BCPS, BCCCP
- Gloria Coronado, PhD
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Project Oncology®
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
- Namrata Vijayvergia, MD
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
Project Oncology®
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
- Namrata Vijayvergia, MD
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target